KEVIN MCGUINESS PLLC for TEVA PHARMACEUTICALS USA INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 515, the Patent Reform Act of 2009 S. 369, the Preserve Access to Affordable Generics Act H.R. 1427, the Promoting Innovation and Access to Life-Saving Medicine Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN MCGUINESS New | — |
Pharmacy PHA
S. 515, the Patent Reform Act of 2009 S. 369, the Preserve Access to Affordable Generics Act H.R. 1427, the Promoting Innovation and Access to Life-Saving Medicine Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN MCGUINESS New | — |
Health Issues HCR
S. 515, the Patent Reform Act of 2009 S. 369, the Preserve Access to Affordable Generics Act H.R. 1427, the Promoting Innovation and Access to Life-Saving Medicine Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN MCGUINESS New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| THROUGH TEVA PHARMACEUTICALS EUROPE, BV | Netherlands | Netherlands | 100.0% | — |
| TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Israel | Israel | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.